

Marialuisa Sensi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6053080/publications.pdf>

Version: 2024-02-01

58
papers

2,514
citations

257450

24
h-index

197818

49
g-index

58
all docs

58
docs citations

58
times ranked

3465
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles. <i>Journal of Investigative Dermatology</i> , 2022, 142, 3030-3040.e5.	0.7	6
2	Genetic Variants and Somatic Alterations Associated with MITF-E318K Germline Mutation in Melanoma Patients. <i>Genes</i> , 2021, 12, 1440.	2.4	2
3	miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFκB-mediated inflammatory mediators. <i>Cell Communication and Signaling</i> , 2020, 18, 156.	6.5	18
4	microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response. <i>Genes</i> , 2016, 7, 124.	2.4	8
5	Axl in ovarian cancer: a step forward for clinical breakthrough?. <i>Oncotarget</i> , 2016, 7, 80105-80106.	1.8	0
6	A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. <i>Oncotarget</i> , 2015, 6, 5118-5133.	1.8	37
7	Novel Axl-driven signaling pathway and molecular signature characterize high-grade ovarian cancer patients with poor clinical outcome. <i>Oncotarget</i> , 2015, 6, 30859-30875.	1.8	32
8	Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression. <i>Cancer Research</i> , 2014, 74, 130-140.	0.9	27
9	Functional characterization of NTRK1 mutations identified in melanoma. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 875-880.	2.8	24
10	Subtype-dependent prognostic relevance of an interferon-induced pathway metagene in node-negative breast cancer. <i>Molecular Oncology</i> , 2014, 8, 1278-1289.	4.6	39
11	An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor response. <i>BMC Genomics</i> , 2013, 14, 508.	2.8	21
12	DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells. <i>Endocrine-Related Cancer</i> , 2013, 20, 23-37.	3.1	41
13	EGFR/MEK/ERK/CDK5-dependent integrin-independent FAK phosphorylated on serine 732 contributes to microtubule depolymerization and mitosis in tumor cells. <i>Cell Death and Disease</i> , 2013, 4, e815-e815.	6.3	39
14	AMPK activators inhibit the proliferation of human melanomas bearing the activated MAPK pathway. <i>Melanoma Research</i> , 2012, 22, 341-350.	1.2	38
15	Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFκB pathway in advanced-stage epithelial ovarian cancer. <i>Oncogene</i> , 2012, 31, 4139-4149.	5.9	108
16	TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells. <i>Oncogene</i> , 2011, 30, 3011-3023.	5.9	78
17	Human Cutaneous Melanomas Lacking MITF and Melanocyte Differentiation Antigens Express a Functional Axl Receptor Kinase. <i>Journal of Investigative Dermatology</i> , 2011, 131, 2448-2457.	0.7	122
18	Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma. <i>Forum on Immunopathological Diseases and Therapeutics</i> , 2011, 2, 179-188.	0.1	14

#	ARTICLE	IF	CITATIONS
19	IGFBP7: an oncosuppressor gene in thyroid carcinogenesis. <i>Oncogene</i> , 2010, 29, 3835-3844.	5.9	69
20	Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5. <i>International Immunology</i> , 2009, 21, 257-268.	4.0	25
21	CD8+ T lymphocytes isolated from renal cancer patients recognize tumour cells through an HLA- and TCR/CD3-independent pathway. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1065-1076.	4.2	7
22	APAF-1 signaling in human melanoma. <i>Cancer Letters</i> , 2006, 238, 168-179.	7.2	37
23	Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. <i>Oncogene</i> , 2006, 25, 3357-3364.	5.9	157
24	Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell-Mediated Patient-Specific Immunotherapy. <i>Clinical Cancer Research</i> , 2006, 12, 5023-5032.	7.0	64
25	Coexpression of NRASQ61R and BRAFV600E in Human Melanoma Cells Activates Senescence and Increases Susceptibility to Cell-Mediated Cytotoxicity. <i>Cancer Research</i> , 2006, 66, 6503-6511.	0.9	81
26	Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype. <i>Cancer Research</i> , 2005, 65, 632-40.	0.9	26
27	Identification of a novel gp100/pMel17 peptide presented by HLA-A*6801 and recognized on human melanoma by cytolytic T cell clones. <i>Tissue Antigens</i> , 2002, 59, 273-279.	1.0	8
28	Human Melanocytes and Melanomas Express Novel mRNA Isoforms of the Tyrosinase-Related Protein-2/DOPAchrome Tautomerase Gene: Molecular and Functional Characterization. <i>Journal of Investigative Dermatology</i> , 2000, 115, 48-56.	0.7	17
29	High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition. <i>Cancer Immunology, Immunotherapy</i> , 1999, 48, 39-46.	4.2	18
30	Translation of a Retained Intron in Tyrosinase-related Protein (TRP) 2 mRNA Generates a New Cytotoxic T Lymphocyte (CTL)-defined and Shared Human Melanoma Antigen Not Expressed in Normal Cells of the Melanocytic Lineage. <i>Journal of Experimental Medicine</i> , 1998, 188, 1005-1016.	8.5	131
31	Intralesional Selection of T Cell Clonotypes in the Immune Response to Melanoma Antigens Occurring During Vaccination. <i>Journal of Immunotherapy</i> , 1998, 21, 198-204.	2.4	10
32	Interaction with fibronectin regulates cytokine gene expression in human melanoma cells. , 1996, 66, 110-116.		14
33	Conserved TCR usage by HLA-Cw*1601-restricted T cell clones recognizing melanoma antigens. <i>International Immunology</i> , 1996, 8, 1463-1466.	4.0	20
34	Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses. <i>Trends in Immunology</i> , 1995, 16, 588-595.	7.5	83
35	BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. <i>Immunity</i> , 1995, 2, 167-175.	14.3	532
36	Effect of protein kinase C inhibitors on invasiveness of human melanoma clones expressing different levels of protein kinase C isoenzymes. <i>International Journal of Cancer</i> , 1994, 57, 281-286.	5.1	25

#	ARTICLE	IF	CITATIONS
37	Cytotoxic T lymphocytes recognize tumor antigens of a murine colonic carcinoma by using different T-cell receptors. <i>International Journal of Cancer</i> , 1994, 57, 440-447.	5.1	14
38	H-2Kb ANDH-2Db gene transfections in B16 melanoma differently affect non-immunological properties relevant to the metastatic process. Involvement of integrin molecules. <i>International Journal of Cancer</i> , 1994, 59, 269-274.	5.1	16
39	Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw* 1601. <i>European Journal of Immunology</i> , 1994, 24, 2134-2140.	2.9	221
40	Expansion of Major Histocompatibility Complex-Restricted Antimelanoma Cytotoxic T-Cell Lymphocyte Clones with Identical T-Cell Receptor from Tumor-Infiltrating Lymphocytes. <i>Journal of Immunotherapy</i> , 1992, 12, 207-211.	2.4	5
41	Immunological and non-immunological influence of H-2Kb gene transfection on the metastatic ability of B16 melanoma cells. <i>International Journal of Cancer</i> , 1991, 48, 270-276.	5.1	27
42	T lymphocytes can mediate lysis of autologous melanoma cells by multiple mechanisms: Evidence with a single T cell clone. <i>Cancer Immunology, Immunotherapy</i> , 1990, 32, 13-21.	4.2	17
43	Mouse tumors are heterogeneous in their susceptibility to syngeneic lymphokine-activated killer cells and delineate functional subsets in such effectors. <i>Cancer Immunology, Immunotherapy</i> , 1990, 31, 37-43.	4.2	6
44	Eradication of a disseminated mouse lymphoma by 1,3-BIS(2-chloroethyl)-1-nitrosourea is immunologically mediated and accompanied by de novo generation of anti-tumor cytotoxicity. <i>International Journal of Cancer</i> , 1990, 46, 1088-1094.	5.1	4
45	Potential of adoptive immunotherapy by cisplatin, but not by doxorubicin, on a disseminated mouse lymphoma and its association with reduction of tumor burden. <i>International Journal of Cancer</i> , 1988, 42, 952-957.	5.1	21
46	Defective T helper activity in the spleen of BALB/c mice immune to a syngeneic fibrosarcoma. <i>Cancer Immunology, Immunotherapy</i> , 1987, 24, 237-43.	4.2	2
47	Transcription of a T cell receptor β chain gene in L cell fibroblasts following DNA-mediated gene transfer. <i>European Journal of Immunology</i> , 1987, 17, 1371-1374.	2.9	2
48	Treatment of a low immunogenic experimental tumour with alloactivated or tumour-immune lymphocytes. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1987, 907, 163-174.	7.4	3
49	Analysis of the cellular immune response to and adoptive immunotherapy of a BALB/c lymphoma that cross-reacts with normal DBA/2 cells. <i>Cancer Immunology, Immunotherapy</i> , 1986, 21, 199-204.	4.2	6
50	Adoptive immunotherapy of cancer with immune and activated lymphocytes: Experimental and clinical studies. <i>Research in Clinic and Laboratory</i> , 1986, 16, 1-20.	0.3	7
51	Allostimulation-induced tumor cytotoxic cells: from mouse to man. <i>Trends in Immunology</i> , 1985, 6, 215-218.	7.5	10
52	DBA/2-like minor histocompatibility antigens on a BALB/c lymphoma. A balb/c anti-DBA/2 serum which lyses the tumor and blocks balb/c anti-tumor and anti-DBA/2 effectors. <i>International Journal of Cancer</i> , 1985, 36, 617-622.	5.1	4
53	LACK OF H-2Ld LOCUS PRODUCTS ON A BALB/c FIBROSARCOMA EXPRESSING H-2k-LIKE ALIEN ANTIGENS. <i>International Journal of Immunogenetics</i> , 1983, 10, 115-125.	1.2	5
54	In vitro detection of cell-mediated immunity to individual tumor-specific antigens of chemically induced BALB/c fibrosarcomas. <i>International Journal of Cancer</i> , 1983, 31, 483-489.	5.1	22

#	ARTICLE	IF	CITATIONS
55	Cross-reactions between tumor cells and allogeneic normal tissues. inhibition of a syngeneic lymphoma outgrowth in h-2 and non-h-2 alloimmune balb/c mice. International Journal of Cancer, 1982, 29, 323-332.	5.1	26
56	Lysis of autologous human melanoma cells by in vitro allosensitized peripheral blood lymphocytes. Cancer Immunology, Immunotherapy, 1982, 14, 99-104.	4.2	31
57	Original H-2d and alien H-2k-like antigens of a BALB/c fibrosarcoma as defined by in vitro and in vivo studies of cell-mediated immunity. European Journal of Immunology, 1980, 10, 671-678.	2.9	12
58	Alien histocompatibility antigens on tumor cells. Immunogenetics, 1979, 9, 1-23.	2.4	75